12 assets in Human Papillomavirus-Related Penile Squamous Cell Carcinoma

Therapeutic assets addressing Human Papillomavirus-Related Penile Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Human Papillomavirus-Related Penile Squamous Cell Carcinoma	Christian Hinrichs	P2	B (58)
e7 tcr-t cells Human Papillomavirus-Related Penile Squamous Cell Carcinoma	Christian Hinrichs	P2	B (58)
Fludarabine Human Papillomavirus-Related Penile Squamous Cell Carcinoma	Christian Hinrichs	P2	B (58)
Atezolizumab Human Papillomavirus-Related Penile Squamous Cell Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
scg142 Human Papillomavirus-Related Penile Squamous Cell Carcinoma	SCG Cell Therapy Pte. Ltd.	P1/2	CC (45)
Tsc-200-A0201 Human Papillomavirus-Related Penile Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-201-B0702 Human Papillomavirus-Related Penile Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-202-A0201 Human Papillomavirus-Related Penile Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-203-A0201 Human Papillomavirus-Related Penile Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-A0101 Human Papillomavirus-Related Penile Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-A0201 Human Papillomavirus-Related Penile Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-C0702 Human Papillomavirus-Related Penile Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)